These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 28679689)
1. Two different, mutually exclusively distributed, Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689 [TBL] [Abstract][Full Text] [Related]
2. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Auer K; Bachmayr-Heyda A; Aust S; Grunt TW; Pils D Cancer Lett; 2017 Mar; 388():158-166. PubMed ID: 27940126 [TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
4. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related]
5. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Eckert MA; Pan S; Hernandez KM; Loth RM; Andrade J; Volchenboum SL; Faber P; Montag A; Lastra R; Peter ME; Yamada SD; Lengyel E Cancer Discov; 2016 Dec; 6(12):1342-1351. PubMed ID: 27856443 [TBL] [Abstract][Full Text] [Related]
6. Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. Singh N; Faruqi A; Kommoss F; McCluggage WG; Trevisan G; Senz J; Lum A; Gilks CB; Anglesio M Mod Pathol; 2018 Apr; 31(4):652-659. PubMed ID: 29148539 [TBL] [Abstract][Full Text] [Related]
7. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522 [TBL] [Abstract][Full Text] [Related]
9. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma. Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306 [TBL] [Abstract][Full Text] [Related]
10. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Zhang S; Dolgalev I; Zhang T; Ran H; Levine DA; Neel BG Nat Commun; 2019 Nov; 10(1):5367. PubMed ID: 31772167 [TBL] [Abstract][Full Text] [Related]
11. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Przybycin CG; Kurman RJ; Ronnett BM; Shih IeM; Vang R Am J Surg Pathol; 2010 Oct; 34(10):1407-16. PubMed ID: 20861711 [TBL] [Abstract][Full Text] [Related]
12. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067 [TBL] [Abstract][Full Text] [Related]
13. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
14. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388 [TBL] [Abstract][Full Text] [Related]
15. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern. Kim HN; Woo HY; DO SI; Kim HS In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396 [TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838 [TBL] [Abstract][Full Text] [Related]
17. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors]. Wen J; Shi JL; Shen DH; Chen YX; Song QJ Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451 [TBL] [Abstract][Full Text] [Related]
18. [Serous genital carcinoma: molecular pathogenesis and the role of tubal fimbria]. Lax S Pathologe; 2009 Dec; 30 Suppl 2():210-6. PubMed ID: 19859709 [TBL] [Abstract][Full Text] [Related]
19. Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. Anglesio MS; O'Neill CJ; Senz J; Gilks CB; McCluggage WG Histopathology; 2017 Dec; 71(6):1014-1017. PubMed ID: 28746984 [No Abstract] [Full Text] [Related]
20. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Auer K; Bachmayr-Heyda A; Aust S; Sukhbaatar N; Reiner AT; Grimm C; Horvat R; Zeillinger R; Pils D Oncotarget; 2015 Jul; 6(19):17261-75. PubMed ID: 25991672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]